心脏再同步治疗在心力衰竭中的作用:叙述性综述
Olivier Uwishema1, Ece Karabulut1,2, Dalal Sheikhah1,3
1Department of Research and Education, Oli Health Magazine Organization Research and Education Kigali Rwanda.
Health science reports
|January 1, 2025
概括
心脏再同步治疗 (CRT) 显著改善心力衰竭 (HF) 结果,提高生活质量和降低死亡率. 目前正在进行的研究旨在克服挑战,并完善CRT的疗效,以获得更好的患者结果.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 由于心脏缺陷导致组织氧化不足,心力衰竭 (HF) 呈现出显著的发病率和死亡率.
- HF病理生理学涉及复杂的功能障碍,使治疗方法复杂化.
研究的目的:
- 审查心脏再同步治疗 (CRT) 在治疗心力衰竭 (HF) 中的关键方面,应用和影响.
- 分析评估CRT疗效的临床试验,并将其与现有的治疗方法进行比较.
主要方法:
- 通过使用Medline,PubMed Central和Embase数据库进行了全面的文献审查.
- 优先考虑的是最近的出版物 (2010年以后),包括早期的开创性作品.
- 门德利被用于参考管理.
主要成果:
- CRT在多个不同HF患者群体中显示出显著的功能改善和提高生活质量.
- 临床试验始终显示CRT优于药物治疗,显著改善左心室喷射率 (LVEF) 和降低死亡率.
- 患者通常具有LVEF≤35%和QRS持续时间≤150ms,NYHAII-IV类,从CRT中受益.
结论:
- CRT是一种高效的治疗方法,可以改善患者的治疗结果,降低死亡率.
- 患者不反应和技术限制等挑战仍然存在,推动正在进行的研究.
- 未来的努力重点是改进患者选择和优化CRT疗法的有效性,以进一步革新HF护理.
更多相关视频
10:17Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
390
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
11.9K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:26Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338